Stockscreener 앱 받기
37.62
0.44%
0.165
시장 영업 전:
38.40
0.785
+2.09%
전일 마감가:
$37.45
열려 있는:
$37.58
하루 거래량:
1.59M
Relative Volume:
0.63
시가총액:
$4.45B
수익:
$1.29B
순이익/손실:
$251.00M
주가수익비율:
19.05
EPS:
1.9744
순현금흐름:
$-193.86M
1주 성능:
+4.43%
1개월 성능:
-4.99%
6개월 성능:
+7.10%
1년 성능:
+176.78%
1일 변동 폭
$37.51
$38.52
1주일 범위
$32.41
$38.52
52주 변동 폭
$13.42
$41.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
명칭
Indivior Pharmaceuticals Inc
전화
804-379-1090
주소
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
37.62 | 4.43B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.60 | 48.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.12 | 39.63B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.19 | 40.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.44 | 33.34B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.87 | 23.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-07-22 | 재개 | Jefferies | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-23 | 개시 | Piper Sandler | Overweight |
| 2024-04-03 | 개시 | Craig Hallum | Buy |
| 2023-07-13 | 개시 | Northland Capital | Outperform |
모두보기
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Indivior Pharmaceuticals, Inc. Statistics – LSX:A42086 - TradingView
Operating expenses (excl. COGS) of Indivior Pharmaceuticals, Inc. – XETR:E7P - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
INDV Technical Analysis | Trend, Signals & Chart Patterns | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Indivior Pharmaceuticals Inc (INDV) Stock Up 5.1% but GF Value S - GuruFocus
Net margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Quick ratio of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted net income available to common stockholders of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
After tax other income/expense of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Non-controlling/minority interest of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Operating income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Diluted earnings per share (diluted EPS) of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – LSX:A42086 - TradingView
Cash per share of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
ETFs Investing in Indivior Pharmaceuticals, Inc. Stocks - TradingView
EBITDA margin % of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Net income of Indivior Pharmaceuticals, Inc. – LSX:A42086 - TradingView
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY - The Globe and Mail
Indivior Pharmaceuticals Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096 - GlobeNewswire Inc.
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
INDV Stock Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
What to Know About This Fund's $74.8 Million Indivior Sale - The Globe and Mail
Madison Avenue Partners Buys Large Stake in Indivior - HarianBasis.co
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% - The Globe and Mail
Indivior Pharmaceuticals, Inc. Balance Sheet – DUS:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – DUS:E7P - TradingView
Indivior Pharmaceuticals Inc. (INDV) upgraded to strong buy: Here's what you should know - MSN
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After A Strong Multi‑Month Share Price Run - Sahm
Bears are losing control over Indivior Pharmaceuticals Inc. (INDV), here's why it's a 'buy' now - MSN
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Free cash flow of Indivior Pharmaceuticals, Inc. – GETTEX:E7P - TradingView
Equity in earnings of Indivior Pharmaceuticals, Inc. – GETTEX:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:E7P - TradingView
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect? - Yahoo Finance
Indivior launches $175M accelerated share buyback - MSN
Indivior (INDV) Shows Benefits of Sublocade for Opioid Use Disor - GuruFocus
Debt to assets ratio of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Net margin % of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Price to cash flow ratio of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Preferred dividends of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Revenue Breakdown – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Income Statement – MUN:E7P - TradingView
Book value per share of Indivior Pharmaceuticals, Inc. – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Earnings and Revenue – MUN:E7P - TradingView
Indivior Pharmaceuticals, Inc. Balance Sheet – MUN:E7P - TradingView
Monthly addiction shot tied to fewer relapses, hospital visits - Stock Titan
Indivior Pharmaceuticals Inc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Indivior Pharmaceuticals Inc 주식 (INDV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kingsley Stuart A | Director |
Mar 06 '26 |
Buy |
31.86 |
940 |
29,953 |
5,582 |
| Ryan Barbara | Director |
Mar 09 '26 |
Buy |
32.56 |
31 |
1,009 |
5,716 |
| Ryan Barbara | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
1,963 |
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
9.79%
0.00%
자본화:
|
볼륨(24시간):